The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies –CYP2C9 and warfarin as an example

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: Many studies have shown that genetic polymorphisms of the CYP2C9 gene contribute to some of the variability (around 20%) in warfarin dose requirements and therapeutic response to the drug. It is also clear that this effect must be elicited through difference...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Dickinson, Gemma L, Lennard, Martin S, Tucker, Geoffrey T, Rostami-Hodjegan, Amin
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Blackwell Science Inc 2007
Aiheet:
Pharmacokinetics & Pharmacodynamics
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2000610/
https://ncbi.nlm.nih.gov/pubmed/17298479
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2007.02850.x
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia